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Selecting Patients for
Cardiac Resynchronization Therapy
The Fallacy of Echocardiographic Dyssynchrony
Nathaniel M. Hawkins, MBCHB,* Mark C. Petrie, MBCHB, BSC, MD,†
Malcolm I. Burgess, MBCHB, BSC, MD,* John J. V. McMurray, MD‡
Liverpool and Glasgow, United Kingdom
Cardiac resynchronization therapy (CRT) reduces morbidity and mortality in patients with heart failure. Interna-
tional guidelines unanimously endorse QRS prolongation to identify candidates for implantation, based on over
4,000 patients randomized in landmark trials. Small, observational, nonrandomized studies with surrogate end
points have promoted echocardiography as a superior method of patient selection. Over 30 dyssynchrony pa-
rameters have been proposed. Most lack validation in appropriate clinical settings, including demonstration of
short- and long-term reproducibility and intra- and interobserver variability. Prospective multicenter trials have
proved informative in unexpected ways. In core laboratories, parameters exhibit striking variability, poor repro-
ducibility, and limited predictive power. We are concerned that many centers today are using these techniques
to select patients for CRT. Publication density and bias have misinformed clinical decision making. Echocardio-
graphic parameters have no place in denying potentially life-saving treatment or in exposing patients to unnec-
essary risks and draining health care resources. Such measures should not stray beyond the research environ-
ment unless validated in randomized trials with robust clinical end points. The electrocardiogram remains a
simple, inexpensive, and reproducible tool that identifies patients likely to benefit from CRT. Patient selection
must use the parameter prospectively validated in landmark clinical trials: the QRS duration. (J Am Coll Car-
diol 2009;53:1944–59) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.11.062e
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slinical trials of cardiac resynchronization therapy (CRT)
ave demonstrated unequivocal improvements in functional
tatus, morbidity, and mortality (Table 1) (1–10). Interna-
ional guidelines from both Europe and North America are
nanimous in assigning the highest grade of recommenda-
ion (11–15). All guidelines state clearly and simply who
hould receive CRT. Reflecting the landmark clinical trials,
atients should have impaired functional status (New York
eart Association [NYHA] functional class III or IV),
educed left ventricular ejection fraction (LVEF) (0.35),
nd prolonged QRS duration (120 ms).
Despite these considered recommendations, many clini-
ians have rejected international guidelines in favor of
chocardiographic selection criteria. “Reasons” include the
bservation that one-third of patients fail to improve clin-
cally or exhibit favorable echocardiographic remodeling
so-called “nonresponders”). It has been suggested that
chocardiographic measures of mechanical dyssynchrony
ay better identify those likely to respond (16,17). Multiple
rom the *University Hospital Aintree, Liverpool, United Kingdom; †Golden Jubilee
ational Hospital, Glasgow, United Kingdom; and the ‡Western Infirmary, Glas-
ow, United Kingdom.m
Manuscript received August 1, 2008; revised manuscript received October 14,
008, accepted November 2, 2008.chocardiographic techniques have been proposed with a
lethora of publications extolling the virtues of each.
We review the current status of selecting candidates for
RT. What constitutes “response?” What are the strengths
nd weaknesses of echocardiographic indexes of dyssyn-
hrony? How robust are techniques beyond the research
nvironment? Should patients fulfilling accepted criteria but
ithout echocardiographic dyssynchrony be denied life-
aving treatment? Should patients with narrow QRS com-
lexes and echocardiographic dyssynchrony undergo inva-
ive and costly procedures?
he Problem With “Response”
ne-quarter to -half of patients are labeled clinical or
olumetric “nonresponders.” The latter are more frequent,
argely due to selected volumetric cutoffs and varying defi-
itions of clinical response. However, failing to achieve
pecific “response” criteria is not necessarily “nonresponse.”
ithout CRT a patient may have undergone further
dverse remodeling, had more limited exercise tolerance, or
ven be dead. A crucial weakness of echocardiographic
tudies is the absence of hard clinical end points—all-cause
ortality, cardiovascular death, and hospitalizations.
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May 26, 2009:1944–59 The Fallacy of Echocardiographic Dyssynchrony“Response” is itself a flawed dichotomy. All medical
herapies present a continuous spectrum ranging from harm
o benefit. Clinical practice is guided by evidence, the
ighest level of which derives from randomized controlled
rials. The end points of these trials reflect the net effect in
population fulfilling specific inclusion criteria. At the
atient level, individuals either improve, are unchanged, or
eteriorate. No intervention benefits all patients. In popu-
ations with heart failure (HF), angiotensin-converting en-
yme inhibitors cause reverse remodeling, improve symp-
oms, and reduce mortality. However, not every individual
emonstrates reverse remodeling and improved symptoms.
ome individuals may experience hypotension, renal impair-
ent, or hyperkalemia. On the basis of the evidence in
opulations, we prescribe angiotensin-converting enzyme
nhibitors for patients with HF. We do not dwell on
electing which patients will benefit. The arguments apply
qually to drugs and devices. Both should be provided to
atients fulfilling the inclusion criteria of landmark clinical
rials. Differences in health economics threaten these prin-
iples. Unlike drugs, the majority of the lifetime cost for
evices is incurred at implantation. Identifying so-called
nonresponders” is, therefore, attractive to governments,
ealth services, and other payers.
linical Response
linical response is variably defined, often without hard
linical end points such as hospitalization or mortality. The
riginal clinical composite score combined measures of
unctional status with major adverse clinical outcomes
death, hospitalization) and withdrawal of study medication
elating to worsening HF (18). However, a plethora of
ifferent clinical composite end points have emerged, with
omponents including 6-min walking distance (19–27),
eak oxygen consumption (20,28), quality-of-life scores
22,29), and transplantation (19,23,30). Moreover, clinical
easures are subject to placebo effect: 39% of control
ubjects as well as 67% of the treatment group were
esponders in the MIRACLE (Multicenter InSync Ran-
omized Clinical Evaluation) study (5).
olumetric Response
urrogate end points are just that—surrogates. Volumetric
easures reduce sample size, provide mechanistic insights,
nd are objective. The direction and magnitude of remod-
ling relates proportionally to survival (31). Changes in left
entricular (LV) volumes may coincide with clinical im-
rovement after implantation (21,30,32). However, defini-
ions of both remodeling and clinical response are varied,
nd magnitude of either may not reach a specific threshold.
linical response may occur without volumetric change, or
ice versa. Correlations between the 2 are limited. In the
IRACLE trial, change in LV end-diastolic volume and
YHA functional class correlated weakly (r 0.13, p 0.02) (33). Reverse remodeling is greater
n patients with nonischemic car-
iomyopathy (33,34), whereas
linical outcomes improve irre-
pective of HF etiology (5,9,10).
urthermore, echocardiographic
ndexes predict clinical response
ess accurately than reverse re-
odeling (21,22). These dis-
arities all caution against sub-
tituting remodeling for clinical
fficacy. Yu et al. (35) justified
he use of echocardiographic
utcomes by reporting that re-
erse remodeling, but not “soft”
linical parameters, predicted
-year mortality in 141 patients.
owever, after multivariable ad-
ustment, baseline dyssynchrony
ssessed using tissue Doppler
lso failed to predict survival.
easons for “Nonresponse”
he benefits of CRT are not
olely attributable to correction
f baseline dyssynchrony. Nu-
erous factors determine re-
ponse, each varying between in-
ividuals: pacing site, ischemia
nd scar burden, irreparable dys-
unction, device optimization,
nd subsequent medical progress.
ow much each variable con-
ributes to nonresponse is un-
nown. Only a small proportion
f the variance in response may
elate to baseline dyssynchrony.
Lateral lead placement improves reverse remodeling and
unctional capacity compared with anterior locations (36–
8). Tailoring lead position to the area of maximal mechan-
cal delay has also been advocated (39,40). Both strategies
ay not be possible. Positioning is subject to coronary
enous anatomy, lead delivery and stability, pacing thresh-
lds, and phrenic nerve stimulation (36). Procedural limi-
ations are inherent to device therapy.
Coronary artery disease presents many obstacles to
esynchronization. Previous infarction impedes coronary
enous access, particularly to the left marginal vein (41).
igh capture thresholds due to scarring further restrict
ead placement. Aside from technical constraints, global
car burden and extent of viable myocardium directly
orrelate with remodeling after CRT (42,43). In addi-
ion, greater scar density around the pacing site portends
n unfavorable response despite adequate lead thresholds
Abbreviations
and Acronyms
CI  confidence interval
CRT  cardiac
resynchronization therapy
HF  heart failure
IVMD  interventricular
mechanical delay
LV  left ventricle/
ventricular
LVEF  left ventricular
ejection fraction
LVESV  left ventricular
end-systolic volume
LVPEP  left ventricular
pre-ejection period
NYHA  New York Heart
Association
ROC  receiver-operator
characteristic
ROI  region of interest
RT3DE  real-time
3-dimensional
echocardiography
SPWMD  septal-to-
posterior wall motion delay
SRI  strain rate imaging
TDI  tissue Doppler
imaging
T  time to peak strain
To  time to onset peak
velocity
Ts  time to peak systolic
velocity
TSI  tissue
synchronization imaging42,43). Poor recruitment of surrounding myocardium
Inclusion Criteria and Outcomes of CRT Trials
Table 1 Inclusion Criteria and Outcomes of CRT Trials
Study Acronym
(Ref. #) n Design
Follow-Up
(Months)
QRSd
(ms)
Mean QRSd
(ms)
LVEDD
(mm) Echocardiography
LVEF
(%)
NYHA
Functional
Class SR/AF ICD End Points
PATH-CHF (1) 41 Cross-over 1 120 175 32 No cutoff No No cutoff III, IV SR No 6MWT  44 m
p  0.001
MLHFQ 19.3
p  0.001
Peak Vo2 1.8
p  0.001
PATH-CHF II (2) 86 Cross-over 3 120 155 20 No cutoff No 30 II–IV SR Yes 6MWT  47 m
p  0.024
MLHFQ 8.1
p  0.004
Peak Vo2 2.5
p  0.001
MUSTIC-SR (3) 48 Cross-over 3 150 174 20 60 No 35 III SR No 6MWT  73 m
p  0.001
MLHFQ 13.6
p  0.001
Peak Vo2 1.2
p  0.029
MUSTIC-AF (4) 37 Cross-over 3 200 paced 209 18 paced 60 No 35 III AF No 6MWT  32 m
p  0.05
MLHFQ 4.3
p  0.11
Peak Vo2  1.7
p  0.04
MIRACLE (5) 453 Parallel 6 130 166 20 55 No 35 III, IV SR No 6MWT  29 m
p  0.005
MLHFQ 9.0
p  0.001
NYHA
p  0.001
MIRACLE-ICD (6) 369 Parallel 6 130 164 22 55 No 35 III, IV SR Yes 6MWT  2 m
p  0.36
MLHFQ 6.5
p  0.02
NYHA
p  0.007
MIRACLE-ICD II (7) 186 Parallel 6 130 165 23 55 No 35 II SR Yes 6MWT  5 m
p  0.59
MLHFQ 2.6
p  0.49
Peak Vo2 0.3
p  0.87
CONTAK-CD (8) 490 Parallel 6 120 158 26 No cutoff No 35 II–IV SR Yes 6MWT  20 m
p  0.043
MLHFQ 2
p  0.39
Peak Vo2 0.8
p  0.03
COMPANION (9) 1,520 Parallel 16.2 median 120 160 median 60 No 35 III, IV SR Yes Death, admission
HR: 0.81
p  0.015
Death
HR: 0.76
p  0.06
HF death, admission
HR: 0.66
p  0.002
CARE-HF (10) 813 Parallel 29.4 mean 150
120  echocardiography
160 median 30 height
indexed
Yes
(n  92)
35 III, IV SR No Death or MACE
HR: 0.63
p  0.001
Death
HR: 0.64
p  0.002
HF admission
HR: 0.48
p  0.001
AF  atrial fibrillation; CARE-HF  Cardiac Resynchronization in Heart Failure study; COMPANION  Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure study; CRT  cardiac resynchronization therapy; HF  heart failure; HR  hazard ratio; ICD 
implantable cardioverter-defibrillator; LVEDD left ventricular end-diastolic diameter; LVEF left ventricular ejection fraction; MACEmajor adverse cardiovascular events; MIRACLEMulticenter InSync Randomized Clinical Evaluation; MIRACLE-ICDMulticenter InSync
Implantable Cardioversion Defibrillation Randomized Clinical Evaluation; MLHFQ  Minnesota Living with Heart Failure Questionnaire; MUSTIC  Multisite Stimulation in Cardiomyopathies study; NYHA  New York Heart Association; PATH-CHF  Pacing Therapies for
Congestive Heart Failure study; QRSd  QRS duration; SR  sinus rhythm; Vo2  oxygen consumption (ml/min/kg); 6MWT  6-min walk test.
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May 26, 2009:1944–59 The Fallacy of Echocardiographic Dyssynchronyisconnects electrical and mechanical capture. Ischemic
eart disease is consistently an independent predictor of
ack of “response” (using surrogate outcomes) to CRT
19,29,44).
Severely remodeled ventricles are possibly “beyond repair,”
egardless of correctable dyssynchrony (45). Both severe LV
ilation and mitral regurgitation independently predict adverse
emodeling and clinical outcomes (19,46,47). This is not
nexpected. Resynchronization coordinates existing contrac-
ion. Globally dilated, poorly contractile ventricles have limited
apacity for improvement. Meta-analysis of clinical trial data
ay establish whether a diameter exists above which resyn-
hronization is ineffective.
Device programming and optimization contribute to
esponse. The acute hemodynamic benefit of optimizing
trioventricular delay is undeniable. Whether this translates
nto long-term improvements in remodeling, symptoms, or
rognosis is unknown (48). Long-term outcome is also
ictated by major adverse cardiovascular events, develop-
ent of atrial fibrillation, changes in medical therapy, and
uration of follow-up. Given the numerous reasons for
onresponse, we must consider how much incremental
enefit echocardiographic selection may provide, and
hether this will significantly change survival or hard
linical end points.
ow Do We Measure Mechanical
yssynchrony Using Echocardiography?
echanical dyssynchrony may be assessed using conven-
ional M-mode and Doppler echocardiography. Newer
odalities include tissue Doppler imaging (TDI), tissue
ynchronization imaging (TSI), triplane TDI, real-time
-dimensional echocardiography (RT3DE), strain rate im-
ging (SRI), and speckle tracking strain.
hat Are the Limitations of
chocardiographic Parameters?
onventional measurements. Interventricular mechanical
elay (IVMD) is the difference in left and right ventricular
re-ejection periods (LVPEP and RVPEP, respectively),
easured from QRS onset to the beginning of aortic and
ulmonary Doppler velocity curves, respectively (49). Both
VPEP and IVMD reflect a complex interaction between
ystolic function, pre-load, and afterload. Prolonged
VPEP in pulmonary hypertension or right ventricular
ysfunction reduces IVMD and accuracy of assessment
50). Left lateral wall diastolic contraction describes delayed
ateral wall contraction (using M-mode) after onset of diastolic
lling (transmitral Doppler E-wave onset) (10,49,51,52).
oexistence of post-systolic contraction and diastolic relax-
tion signifies severe intraventricular dyssynchrony. Speci-
city is thus high, but sensitivity low.
Septal-to-posterior wall motion delay (SPWMD) mea-
ures time between maximal incursion of the septum and
osterior wall on M-mode, with a delay 130 ms considered pignificant intraventricular dyssynchrony (23,30,51,53–56).
any drawbacks to SPWMD exist. It is 1-dimensional,
omparing only 2 basal segments and neglecting the more
requently delayed lateral wall. Septal motion reflects inter-
entricular in addition to intraventricular dyssynchrony (51).
easibility is variably reported between 55% and 100%
23,30,51,53–56). Maximal septal or posterior wall motion
s often diminished or absent in ischemic populations, causing
naccurate assessment (23,51,54,55). Parasternal acoustic
indows may be inadequate (55). Perpendicular M-mode
ections of the proximal LV are often not possible (23).
DI. TEMPORAL VERSUS SPATIAL DYSSYNCHRONY. TDI
valuates longitudinal myocardial contraction in the basal
nd midsegments from apical 4-, 3-, and 2-chamber views.
ither time to peak systolic velocity (Ts) or time to onset of
ystolic velocity (To) is measured relative to QRS onset.
ntraventricular dyssynchrony is quantified either by the
tandard deviation of 12 segments (Ts-SD-12 or “dyssyn-
hrony index”) or the maximal temporal difference between
(Ts-2, To-2) or more LV segments (e.g., Ts-6, Ts-12).
arger values indicate more severe dyssynchrony.
Variance in timing alone cannot differentiate between
patial patterns of dyssynchrony. Reduced cardiac ejection
ccurs through displacement of blood volume from early to
ate activated regions. More contractile force is accommo-
ated when delayed segments are clustered together. The
et impact is less when delays are dispersed throughout the
entricle (57). Most of the proposed measures also ignore
he apical segments completely.
LIGNMENT. The limitations of TDI are similar to conven-
ional Doppler. Excessive gain causes spectral broadening
nd velocity overestimation. Alignment of the insonating
eam and direction of myocardial movement is crucial.
rror is unavoidable given the limited number of acoustic
indows through the human thorax. Deviation underesti-
ates velocities and creates erroneous peaks through inclu-
ion of nonlongitudinal motion. Alignment is particularly
hallenging in dilated, thinned, and spherically distorted
entricles.
ONGITUDINAL MOTION. Transducer orientation and in-
onation angle restricts TDI assessment to the longitudinal
lane. However, ventricular contraction involves complex
orsional deformation originating in oppositely wound myo-
ardial fiber helices (57,58). In systole, the base rotates
lockwise and apex counterclockwise (58). This wringing
otion combines longitudinal, circumferential, and radial
ectors. Of these, longitudinal indexes have several disad-
antages: low amplitude, greater variance, and limited con-
ribution to systolic function (57).
ULSED-WAVE ANALYSIS. Pulsed-wave and color-coded TDI
re compared in Table 2. Pulsed-wave TDI is widely
vailable and offers high temporal resolution. Sampling is
estricted to a single position during each cardiac cycle,
recluding post-hoc repositioning and analysis. Comparison
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The Fallacy of Echocardiographic Dyssynchrony May 26, 2009:1944–59f multiple segments requires separate acquisitions in dif-
erent cycles, and is limited by differences in heart rate,
oading conditions, and respiration. Atrial fibrillation is
otably problematic (24). By contrast, color-coded TDI
tores time velocity data superimposed on 2-dimensional
ine loops. This allows offline analysis of multiple segments
ithin 1 plane during the same cardiac cycle.
IMING VELOCITIES. Numerous issues confound timing of
issue Doppler velocities relative to the surface electrocar-
iogram. Error may result from imprecise identification of
RS onset, depending on morphology and electrical trace
larity. Measurement from a uniform point on the electro-
ardiogram is recommended if the QRS onset is unclear
59). The period during which to measure peak velocity is
ontroversial. Analysis is typically confined to the ejection
nterval. The issue of post-systolic shortening is particularly
roblematic in ischemic populations. Some groups advocate
xtension into diastole (22,60,61). However, inclusion of
ost-systolic shortening yielded inferior results in compar-
tive studies (62,63).
Inconsistent choice of peak velocity greatly impairs re-
roducibility. Suboptimal image quality, misalignment,
ranslational vectors, and signal noise all create artefacts.
olyphasic or relatively flat velocity contours prevent uni-
orm interpretation. Double peaks are common, especially
n the free walls (64). Selection of the highest peak is
dvised (64–66). However, small variations in double peaks
f similar amplitude often change selection and timing
arkedly (64). A recent study invited 9 expert faculty
embers of an international echocardiography congress to
nalyze velocity traces from 18 consecutive patients (45).
ull agreement was achieved in just 3 cases, with an
ntraclass correlation coefficient of 0.42.
Measuring the time to onset of systolic velocity avoids errors
n identifying peak velocity and is considered a surrogate for
egional electromechanical coupling (46,50,67–70). However,
he onset may be obscured by noise or fuse with the isovolumic
ontraction signal (71). The rationale for measuring time to
nset as opposed to peak velocity depends on the perceived
ifferences Betweenolo -Coded and Pulsed-Wave TDI
Table 2 Differences BetweenColor-Coded and Pulsed-Wave TDI
Color-Coded TDI Pulsed-Wave TDI
Limited availability Wider availability
Myocardial velocities 10% to 20% lower
compared with pulsed-wave TDI
Myocardial velocities 10% to 20% higher
compared with color-coded TDI
Lower temporal resolution Higher temporal resolution
Higher spatial resolution Lower spatial resolution
Rapid acquisition Slower acquisition
Offline analysis Online analysis
Post-hoc sample volume repositioning
possible
Post-hoc sample volume repositioning
impossible
Simultaneous comparison of multiple
segments
Simultaneous comparison of segments
impossible
DI  tissue Doppler imaging.urpose of CRT. The former aims to synchronize ventricular mepolarization, and the latter to synchronize mechanical con-
raction. Few studies have compared strategies, some favoring
ime to onset (67,72), others time to peak (71,73).
OSITIONING REGION OF INTEREST (ROI). Timing and veloc-
ties are neither homogeneous within segments nor abruptly
emarcated between segments. Delayed contraction occurs
n all segments and at all levels of the ventricle. Results are
ritically dependent on the location interrogated. Two
ost-processing steps introduce variability: placement and
racking of the ROI (74). Both lack standardization. Mov-
ng the ROI within segments significantly alters timing.
ean septal-lateral delay (Ts-2) was 28 ms higher when
omparing low-basal and midbasal ROIs in 41 consecutive
atients (p  0.01) (45). Bland-Altman limits of agreement
ere correspondingly wide (129 ms). Recent publications
ow advocate manually adjusting the ROI within the
egment (up or down, left or right) to produce the most
representative” peak velocity (17,59). This is clearly highly
perator dependent and contrasts starkly with the methods
n earlier reports.
Once positioned, the segment of interest moves beneath
stationary ROI during the cardiac cycle. Manual ROI
racking, though time consuming, is required to maintain a
idsegment location and avoid inclusion of the ventricular
avity. Stationary or manual ROI tracking may alter the
ocation of the peak systolic velocity. ROI tracking changed
he diagnosis of dyssynchrony in 3 of 18 patients (17%)
hen using 2- or 12-segment tissue Doppler models (74).
o study examining prediction of response to CRT has
pecified whether or not ROI tracking was used.
EPRODUCIBILITY. Variability arises not only from intraob-
erver and interobserver differences, but also from sonogra-
her technique, echocardiographic machines, and the phys-
ological state of patients. Any index suitable for widespread
creening should be obtainable and reproducible with dif-
erent observers, sonographers, and equipment. Only 2
tudies have reported test–retest reliability (65,71). Intra-
lass correlations were limited, ranging from r 0.26 to r
.56 for 2- and 4-segment tissue Doppler models. More-
ver, wide Bland-Altman confidence intervals (CIs) ex-
eeded the diagnostic cutoffs for the respective criteria (65).
EASIBILITY. Few studies have reported feasibility, given the
forementioned limitations (Table 3). Many enrolled non-
onsecutive patients, or excluded patients with inadequate
easurements from analysis (24,56,67,75). Whether the
igh-quality data acquisition translates to real-world pa-
ients with extensive comorbidity is questionable. Who
rbitrates image quality and by what standards must be
onsidered.
SI. The TSI algorithm automatically detects peak systolic
elocity. Color coding superimposed on real-time images
isplays regional delays, ranging from green (earliest) to red
latest). A quantitative tool automatically calculates the
edian Ts within a manually positioned sample volume,
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May 26, 2009:1944–59 The Fallacy of Echocardiographic Dyssynchronynabling rapid comparison of segments (25,62). As with
raditional TDI, moving the ROI within segments alters the
easured delay. The TSI algorithm detects velocity peaks
ithin a specified time interval. Systole must be manually
efined according to aortic valve opening and closure.
ncorrect timing introduces error through inclusion of peaks
utside of the ejection phase.
riplane TDI. Color-coded TDI only compares opposing
alls within 1 plane. Interrogation of all segments requires
separate acquisitions in orthogonal planes, with unavoid-
ble heart rate variability. A single 3-dimensional triplane
ataset allows simultaneous comparison of all 12 segments
uring the same cardiac cycle. The technique reduces
cquisition time, eliminates heart rate variability, and more
ccurately defines LV volumes (76,77). However, many
nherent TDI failings remain: angle dependency, timing of
eak velocities, ROI positioning, and assessment of only
ongitudinal motion.
T3DE. Dyssynchrony may be characterized without TDI
sing a 3-dimensional model of the LV (78–80). Four
onsecutive cardiac cycles are combined to form a larger
yramidal volume (78,79). Acquisition requires end-
xpiratory breath hold and a stable heart rate to minimize
ranslation artefacts between the 4 subvolumes. Application
n patients with atrial fibrillation or frequent ectopy is
imited. Regional time-volume curves allow measurement of
ime to minimum systolic volume. The standard deviation
f 12 or 16 segments creates a systolic dyssynchrony index,
xpressed as percentage of the cardiac cycle (78–80). The
arameter encompasses longitudinal, radial, and circumfer-
ntial contraction. The problems are different, but no less
ignificant, than those of TDI. Translational artefacts and
uboptimal endocardial delineation often preclude analysis,
onfounding 23% of 100 patients with ischemic cardiomy-
pathy attending a high-volume center (80). Image quality
as deemed optimal in only 34%. Lower frame rates and
emporal resolution impede accurate timing. Time-volume
urves are critically dependent on positioning of the center
oint, and are ambiguous for akinetic segments (80). Dif-
erent software produces different values (78).
RI. TDI myocardial velocities are inherently inaccurate
hrough incorporation of translational cardiac motion, ro-
ation, and tethering by adjacent segments. Strain ()
easures localized myocardial deformation, thus differenti-
ting between passive displacement and active systolic con-
raction. Dyssynchrony is characterized by dispersion of
ime to peak strain (T) between segments, analogous to
DI parameters (e.g., T-SD-12). Strain rate is tradition-
lly derived from tissue Doppler velocities. High signal
oise, artefacts, angle dependence, respiratory drift, and
omplex data processing all overshadow the theoretical
erits (81). The resulting high intraobserver and interob-
erver variability limits reproducibility (63,82). Interpreta-
ion is difficult in ischemic populations as strain delays,
articularly post-systolic shortening, may signify myocardial
schemia or viability rather than dyssynchrony (81). wpeckle tracking. Speckle tracking is a novel method of
uantifying regional strain from routine B-mode gray-scale
mages (58,59,83). Tracking patterns of acoustic markers
speckles) quantify tissue deformation without the direc-
ionality constraints of Doppler techniques. Longitudinal
nd radial function are measured from apical and parasternal
iews, respectively. Several shortcomings exist. High qual-
ty, high frame rate, second harmonic images are required.
mage degradation and through-plane motion both com-
romise speckle tracking (58). Temporal resolution is lower
han TDI techniques. Conventionally, defining the ROI
emains user dependent. The endocardial and epicardial
orders are manually traced and fine-tuned to include all
egments throughout the cardiac cycle (59,83). Further
djustment is undertaken to optimize the tracking stability
core (59). An automated method for analysis has been
eveloped but not yet applied to the assessment of dyssyn-
hrony (84).
greement between modalities. Discordance between
odalities raises further concerns. Studies have compared
DI against M-mode (55), conventional Doppler (72),
T3DE (79,80), and SRI (64). Agreement between mo-
alities is limited (55,64,72,79,80). The reported prevalence
aries significantly, despite recruitment of similar patients.
yssynchrony is often present in asymptomatic normal
ubjects (64). In 2 studies (64,85), the average value of
s-SD-12 in normal subjects exceeded the cutoff proposed
or predicting response. Dyssynchrony appears to be defined
argely by the method of assessment and threshold applied.
redicting Response to Therapy
umerous echocardiographic parameters have been pro-
osed as predictors of response to CRT (Table 3). These
argely derive from retrospective, exploratory analyses in
mall, single-center, nonrandomized studies. Whether or
ot consecutive patients were recruited and observers
linded is often unclear. Interpretation is confounded by
arying definitions of dyssynchrony and response. The
uration of CRT was frequently only 6 months or less,
nadequate for assessing hard clinical end points. Intraobserver
nd interobserver variability are often quoted from previous
tudies or simply not presented. Cutoffs derived from 1 tissue
oppler parameter are inappropriately applied to another:
0 ms from 8- to 2-segment models (46,50); 65 ms from 4- to
-segment models (21,55); 100 ms from 12- to 4-segment
odels (75,86). The majority of evidence derives from 3
cademic programs in Hong Kong (17,62,63,87,88), Leiden
21,25,26,55,76–78,89,90), and Pittsburgh (59,83,91–93).
mong these, it is uncertain whether patients from earlier
tudies were included in subsequent ones. Sensitivity and
pecificity are proportions for which CIs guide interpreta-
ion. Only 2 studies present such intervals (59,83). One
undred percent sensitivity and specificity are meaningless
n small patient groups. In many studies, the lower CI
ould equate to tossing a coin. Results are often overinter-
Design of Studies Investigating Parameters Predicting Response to CRT
Table 3 Design of Studies Investigating Parameters Predicting Response to CRT
First Author (Ref. #) n
Follow-Up
(Months) Prospective
Consecutive
Patients
Blinded
Analysis
Dyssynchrony
Parameter
Cutoff
(ms)
Cutoff
Derivation
Feasibility
(%)
Variability
Intra- Inter-
Conventional parameters
Pitzalis (53) 20 1 Yes Yes Yes SPWMD 130 ROC curve 100 0.96 0.91
Pitzalis (30) 51 14 Yes Yes Yes SPWMD 130 Previous study 93 — —
Marcus (54) 79 6 No No Yes SPWMD 130 Previous study 55 High High
Diaz-Infante (23) 67 6 Yes Yes Yes SPWMD 130 Previous study 79 0.97 0.98
Sassone (51) 48 6 No Yes No SPWMD 130 Previous study 67 — —
LLWDC Present Present/absent 96 — —
Da Costa (95) 67 12 Yes No Yes IVMD 50 Previous study 100 — —
Achilli (46) 133 6 No Yes Yes IVMD 44 ROC curve 100 — —
Duncan (94) 39 6 No No Yes t-IVT — — 100 — —
Tissue Doppler imaging
Bleeker (55) 98 6 No Yes Yes Ts-2 65 Previous study 96 4% 10%
SPWMD 130 Previous study 59 8% 14%
Bax (89) 25 Acute No Yes Yes Ts-2 60 Selected 100 — —
Bleeker (26) 40 6 Yes Yes Yes Ts-2 65 Previous study 100 — —
Soliman (24) 60 12 No Yes Yes Ts-2 pulsed 60 Previous study 93 Low Low
Bax (21) 80 6 No Yes Yes Ts-4 65 ROC curve 100 — —
Heist (75) 39 Acute No Yes No dP/dt 600 mm Hg/s Previous study — — —
Ts-4 100 Previous study
Notabartolo (22) 49 3 No Yes No Ts-6 110 EP study 100 — —
Yuan (109) 18 3 Yes Yes Yes Ts-6 annular 105 ROC curve 100 — —
Yu (87) 30 3 No No No Ts-SD-12 32.6 2 SD controls 100 5% 5%
Yu (63) 54 3 No No No Ts-SD-12 31.4 ROC curve 100 3% 5%
Yu (88) 55 3 No No No Ts-SD-12 31.4 ROC curve 100 — —
Ts-12 98.5 ROC curve
Yu (17) 256 6 No No Yes Ts-SD-12 33 ROC curve 100 5% 10%
Ts-12 100 ROC curve
Ts-2 60 ROC curve
De Boeck (45) 41 7 Yes Yes Yes Ts-SD-12 32 Previous study 100 13% —
Ts-2 60 Previous study 100 11% —
IVMD 40 Previous study 100 14% —
Strain-2 150 Previous study 100 9% —
Penicka (69) 49 6 Yes Yes Yes To-3 60 ROC curve 100 7% 9%
To LV-RV 56 ROC curve 100 6% 7%
To sum 102 ROC curve 100 — —
Jansen (67) 69 3 No Yes No To-SD-6 20 ROC curve 100 3% 5%
To-6 60 ROC curve 100
Jansen (110) 53 3 No Yes Yes Shuffle Present Present/absent 100 6% 11%
Cannesson (91) 23 8 Yes Yes No Velocity vector 75 ROC curve 92 3% 4%
Continued on next page
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Table 3 Continued
First Author (Ref. #) n
Follow-Up
(Months) Prospective
Consecutive
Patients
Blinded
Analysis
Dyssynchrony
Parameter
Cutoff
(ms)
Cutoff
Derivation
Feasibility
(%)
Variability
Intra- Inter-
Tissue synchronization imaging
Tada (61) 22 27 No No No TSI Ts Sep Lat 150 Selected 100 — —
Gorcsan (92) 29 Acute Yes Yes No TSI Ts-2 65 ROC curve 100 4% 6%
Van de Veire (25) 60 6 No Yes Yes TSI Ts-2 65 Previous study 100
Yu (62) 56 3 No No No TSI Ts-SD-12 34.4 ROC curve 100 4% 6%
TSI Ts-12 105 ROC curve 100
TSI Ts-SD-6 34.5 ROC curve 100
TSI Ts-6 78 ROC curve 100
3-dimensional
Van de Veire (77) 49 Acute No Yes No 3D Ts-SD-12 35.8 ROC curve 100 — —
Van de Veire (76) 60 6 No Yes No 3D Ts-SD-12 33 ROC curve 100 — —
Marsan (78) 56 Acute No Yes Yes 3D SDI 5.6 ROC curve 93 Low Low
Strain rate imaging
Porciani (98) 59 6 Yes No No oExcT 760 ROC curve 89 — 0.97
Ts-SD-12 32 ROC curve — — —
Mele (56) 37 6 Yes Yes Yes T-SD-12 60 Median 97 0.99 0.97
T-2 Sep-Post 194 Median 87 0.97 0.99
Dohi (93) 38 Acute No Yes No T-2 Sep-Post 130 Selected 97 2% 4%
Capasso (27) 28 12 Yes Yes No T-2 — — — — —
Speckle tracking
Knebel (101) 38 9 No No No T-6 — — 100 — —
Ts-6 105 ROC curve 100 — —
Suffoletto (83) 50 8 Yes Yes No T-2 Sep-Post 130 ROC curve 94 6% 8%
Gorcsan (59) 176 6 Yes Yes Yes T-2 Sep-Post 130/60 ROC curve 93 — —
Delgado (90) 161 6 No Yes No T-2 Sep-Post 130 ROC curve 85 0.98 0.97
CRT cardiac resynchronization therapy; dP/dt delta pressure/delta time; EP electrophysiological; IVMD interventricular mechanical delay; Lat lateral; LLWDC left lateral wall diastolic contraction; LV left ventricular; oExcT total time of segmental contraction
exceeding aortic valve closure Post  posterior; ROC  receiver-operator characteristic; RV  right ventricular; SDI  systolic dyssynchrony index; Sep  septal; SPWMD  septal-to-posterior wall motion delay; T  time to peak strain; t-IVT  total isovolumic time; To 
time to onset peak velocity; Ts  time to peak systolic velocity; TSI  tissue synchronization imaging; 3D  3-dimensional.
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ot simply the play of chance.
redicting response using conventional parameters.
chocardiographic inclusion criteria in the CARE-HF
Cardiac Resynchronization in Heart Failure) study were in
ddition to, rather than replacing, intermediate QRS pro-
ongation (120 to 150 ms) (10). Ninety-two (11%) patients
ere enrolled, requiring 2 of 3 echocardiographic indicators
f dyssynchrony: LVPEP 140 ms, IVMD 40 ms, or left
ateral wall diastolic contraction. By definition IVMD and
VPEP are highly interdependent, demonstrating col-
inearity in multivariate models (45).
A number of small, single-center studies observed no
orrelation between remodeling after CRT and IVMD,
ssessed using conventional or tissue Doppler (21,51,63).
owever, in other reports, IVMD predicted both clinical
nd volumetric response (45,94,95). Two multicenter stud-
es have confirmed the importance of IVMD. The Italian
CART (Selection of CAndidates to cardiac Resynchroni-
ation Therapy) trial retrospectively analyzed 6-month out-
omes in 133 consecutive patients, defining response by
linical composite score combined with improved LVEF
5% (46). Multivariate analysis identified longer IVMD as
n independent predictor of positive response (odds ratio:
.017 [95% CI: 1.005 to 1.029], p  0.007). However,
ensitivity and specificity were limited using the receiver-
perator characteristic (ROC)-derived cutoff of 44 ms (66%
nd 55%, respectively). In the CARE-HF trial, prolonged
VMD was an independent predictor of response to CRT
hazard ratio: 0.99 [95% CI: 0.98 to 1.00], p  0.0084)
96). A degree of caution is warranted, as both analyses were
xploratory, and the interactions between IVMD and re-
ponse were limited.
In 2 studies, SPWMD 130 ms predicted reverse
emodeling in patients with predominantly nonischemic
ardiomyopathy (n  20 and n  60) (30,53). Predictive
ccuracy (84% and 85%) and correlation between SPWMD
nd volumetric change were remarkably consistent. In the
arger study, SPWMD 130 ms independently predicted
ong-term clinical improvement after CRT (median
ollow-up 14 months) (30). Five subsequent studies un-
quivocally refuted the clinical applicability and predictive
alue of SPWMD (23,51,54–56). Feasibility ranged from
ust 55% to 79% (Table 3). Baseline SPWMD consistently
ailed to differentiate between responders and nonre-
ponders, or correlate with LV remodeling. Sensitivity
anged from 24% to 66%, and specificity from 38% to 66%.
redicting response using TDI. The simplest tissue
oppler assessment, septal-to-lateral delay (Ts-2), pre-
icted short-term remodeling and symptomatic response in
tudies from 3 centers (17,26,55,63,89). A retrospective
nalysis combined data from 256 patients attending these
enters (17). Septal-to-lateral delay predicted LV remodel-
ng at 6 months with a sensitivity of 70% and specificity of
6%. Less favorable results were obtained elsewhere in 60
nd 41 patients (24,45). Sensitivity for identifying remod- tling over similar time periods ranged from 33% to 62%,
nd specificity from 23% to 65%. Beyond the inherent
imitations of TDI described previously, 2-segment models
lso neglect the majority of delayed segments. Interrogating
ore segments improved predictive accuracy in comparative
tudies (17,45,63,67).
The maximum time difference between peak systolic
elocities in 4 basal segments (Ts-4) was examined in 85
atients (21). Dyssynchrony 65 ms yielded a sensitivity
nd specificity of 80% to predict clinical improvement and
f 92% to predict reverse remodeling. Patients with dyssyn-
hrony had improved prognosis compared with those with-
ut (6% vs. 50% 1-year mortality or HF hospitalization, p
.001). Contrary evidence emerged from the Italian multi-
enter SCART trial (46). Time to onset of systolic velocity
as measured using pulsed-wave Doppler in 133 consecu-
ive patients. Septal-to-lateral delay (To-2) failed to predict
he composite clinical and remodeling end point in multi-
ariate analysis. Subgroup analysis further discredited TDI
echniques (68). Despite employing a more complex 6 basal
egment model, neither clinical nor volumetric response
iffered in patients with dyssynchrony.
Yu et al. (17,62,63,87,88,97) have championed the 12-
egment “dyssynchrony index” (Ts-SD-12). All but 1 report
ssessed remodeling at 3 months, defined as reduction in left
entricular end-systolic volume (LVESV) by 15% (17). The
riginal study included 30 patients (87). The dyssynchrony
ndex was the only independent predictor of reverse remod-
ling, with a pre-implant cutoff of 32.6 ms completely
eparating responders from nonresponders. Four subsequent
eports included 54, 55, 56, and 58 patients, all with similar
aseline characteristics (62,63,88,97). Whether separate pa-
ient cohorts were involved is unclear. For predicting re-
odeling, sensitivity ranged from 94% to 100%, and spec-
ficity from 78% to 100% (63,87,88,97). Accuracy was
imilar in a combined analysis of 256 patients attending the
niversities of Hong Kong, Leiden, and Pittsburgh (17).
hether comparable results are attainable beyond academic
nstitutions is doubtful. Two other single-center studies
ave failed to reproduce such high predictive values (45,98).
s-SD poorly predicted volumetric remodeling after 6
onths in 41 and 59 patients. Sensitivity was reasonable
83% and 82%, respectively) but specificity poor (24% and
9%, respectively). As discussed later, the feasibility, repro-
ucibility, and predictive accuracy of tissue Doppler param-
ters were shown to be inadequate in the multicenter
ROSPECT (Predictors of Response to Cardiac Resyn-
hronization Therapy) trial (99).
redicting response using TSI. The Hong Kong and
eiden groups compared automatic TSI and manual TDI
arameters in 56 and 60 patients, respectively (25,62). High
orrelations validated the TSI software (r 0.97 and r 0.95,
espectively, both p  0.001). Baseline TSI dyssynchrony was
ignificantly greater in responders (25,62), and correlated with
olumetric change after CRT (Table 4) (62,100,101). Predic-
ive accuracy for remodeling was similar in 2-, 6-, and
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May 26, 2009:1944–59 The Fallacy of Echocardiographic Dyssynchrony2-segment parameters. Furthermore, the method of quanti-
ying dispersion was only of minor importance. Measurement
f standard deviation or range yielded similar overall accuracy
nd correlations in both the 6- and 12-segment models. No
ulticenter or randomized trial has employed TSI techniques.
redicting response using triplane TDI. One group has
ssessed acute and longer-term prediction of response using
riplane TDI (76,77). Close correlations were noted between
onventional and triplane Ts measurements (r between 0.94
nd 0.98, p  0.001). In 60 consecutive patients, Ts-SD-12
redicted improvement in NYHA functional class at 6 months
ith 89% sensitivity and 82% specificity (76).
redicting response using 3-dimensional echocardio-
raphy. Studies have demonstrated short-term improvement
n dyssynchrony and predicted acute volumetric response using
-dimensional echocardiography (78,79,102). None has as-
essed prediction of longer-term response.
redicting response using SRI. The evidence supporting
issue Doppler-derived strain is no less contradictory than for
issue Doppler techniques. Three nonrandomized, single-
enter studies reported positive results using different strain
arameters (56,93,98). Utilizing T in 38 and 37 patients,
espectively, delay between anteroseptal and posterior walls
redicted acute increase in stroke volume (93), while the
tandard deviation of 12 segments correlated with remodeling
months after CRT (r  0.73, p  0.001) (56). The third
eport proposed a novel parameter reflecting the total time of
egmental contraction exceeding aortic valve closure (98). A
utoff of 760 ms predicted 6-month remodeling with 94%
ensitivity and 83% specificity.
Three reports by Yu et al. (17,63,88) contest the utility of
RI. All tissue Doppler, but no strain rate measurements,
redicted 3-month remodeling when comparing 18 parame-
ers (63). The largest study included 256 patients attending 3
cademic centers (17). Again, none of the longitudinal strain
arameters predicted reverse remodeling after 6 months. The
reas under the ROC curves barely deviated from the “no
tility” value of 0.50 (range 0.49 to 0.53, all p  NS).
redicting response using speckle tracking. Once more,
he evidence is conflicting. Three studies from Leiden and
ittsburgh found that delay 130 ms in peak septal-to-
osterior wall radial strain predicted remodeling after at least 6
onths, defined by15% improvement in LVEF or LVESV
59,83,90). Sensitivity ranged from 83% to 89%, and specificity
rom 73% to 83%. Speckle tracking and TDI methods were
ighly correlated (r 0.94, p 0.001) (83). However, neither
emonstrated clear superiority (83,90). A German single-
enter study contradicted these positive results (103). Both
adial and longitudinal speckle tracking strain failed to predict
everse remodeling 6 months after CRT in 38 patients.
ill Combining Parameters
mprove Patient Selection?
o single parameter will completely dictate CRT response.
ome have proposed combining methods or using scoring systems (59,69,75,104). In the Pittsburgh speckle tracking
tudy, combining longitudinal and radial measures predicted
jection fraction response with 88% sensitivity and 80%
pecificity, significantly better than either technique alone
59). The St. Mary’s protocol from London selected from 2
ajor and 6 minor dyssynchrony criteria, mixing conven-
ional and tissue Doppler measures of intraventricular and
nterventricular dyssynchrony alongside QRS duration
104). No formal validation was published. Scores encom-
assing periprocedural variables are limited in selecting
atients before implantation (75).
he PROSPECT Study:
redictors of Response to CRT
he multicenter PROSPECT trial was expected to inform
he cardiology community of the best echocardiographic
redictor of response to CRT (99). The trial proved to be
ore informative than expected. All 53 centers in the U.S.,
urope, and Hong Kong obtained independent accredita-
ion before enrollment of nearly 500 patients. A specific
chocardiographic protocol was approved by the steering
ommittee. The robust study design incorporated site train-
ng in acquisition methods and blinded analysis in 3 core
nternational laboratories.
The study exposed critical limitations in the 12 echocar-
iographic measures of dyssynchrony and questioned the
alidity of previous single-center experience. Feasibility of
issue Doppler measurements was poor, with the percent of
ndividual parameters deemed interpretable ranging from
ust 37% to 82%. Studies considered uninterpretable by the
ore laboratories were excluded from further analysis. Even
mong evaluable echocardiograms, the lack of reproducibil-
ty was striking. For 6- and 12-segment TDI models, the
espective intraobserver variability was 16% and 11%, and
nterobserver variability was 32% and 34%. Differences in
chocardiographic platforms and equipment were also ap-
arent. TDI data obtained with the Siemens (Malvern,
ennsylvania) machines were excluded from analysis be-
ause of suboptimal data quality as determined by the core
aboratories (99).
As well as lacking reproducibility, the parameters also
acked meaningful predictive value. Sensitivity for identify-
ng improvement in clinical composite score ranged from
% to 74%, and specificity from 35% to 91%. Prediction of
everse remodeling, defined as reduction in LVESV by 15%,
as no better. For all parameters, the area under the ROC
urve for positive clinical or volumetric response was 0.62.
everal explanations for the findings have been postulated.
hese include differences in the study population compared
ith those of previous reports and unfamiliarity with pa-
ameters of dyssynchrony at the individual centers. None-
heless, the extensive training ensured that quality was far
bove that expected in routine clinical practice. The results
ake it impossible to endorse any echocardiographic mea-ure of dyssynchrony to select patients for CRT.
Parameters of Systolic Dyssynchrony Predicting Response to CRT
Table 4 Parameters of Systolic Dyssynchrony Predicting Response to CRT
First Author (Ref. #) Responder Definition % Nonresponders
Dyssynchrony
Parameter
Responders vs. Nonresponders Correlation* Accuracy
Parameter (ms) p Value r p Value Sn Sp
Conventional parameters
Pitzalis (53) 15% LVESV 40 SPWMD 246 vs. 110 0.001 0.70 0.001 100 63
Pitzalis (30) 5% LVEF 53 SPWMD — — 0.69 0.0001 92 78
Marcus (54) 15% LVESV — SPWMD 77 vs. 59 0.63 0.10 0.41 24 66
Diaz-Infante (23) Death, transplant, 6MWT 10% 25 SPWMD 158 vs. 144 0.7 — — 47 48
15% LVESV 56 SPWMD — — 0.2 0.1 50 38
Sassone (51) 15% LVESV 35 SPWMD 96 vs. 108 0.555 — — — —
LLWDC 9 vs. 12 0.003 Independent predictor
IVMD 46 vs. 52 0.308 — — — —
Da Costa (95) HF death or admission, transplant 30 IVMD 64 vs. 57 0.09 Independent predictor
Achilli (46) 5% LVEF, Clinical Score 32 IVMD 52 vs. 36 0.029 66 55
Duncan (94) NYHA 1 26 t-IVT 16 vs. 9 (s/min) 0.001 — — — —
IVMD 59 vs. 9 0.001 — — — —
Tissue Doppler imaging
Bleeker (55) NYHA 1 23 Ts-2 103 vs. 41 0.05 — — 90 82
SPWMD 188 vs. 155 NS — — 66 50
Bax (89) 5% LVEF 32 Ts-2 86 vs. 39 0.01 0.47 0.017 76 88
Bleeker (26) NYHA 1 and 6MWT 25% 40 Ts-2 — — Independent predictor
Soliman (24) NYHA 1 and 6MWT 25% 17 Ts-2 pulsed — — — — 62 20
15% LVESV 22 Ts-2 pulsed 81 vs. 78 NS — — 62 23
Bax (21) NYHA 1 and 6MWT 25% 26 Ts-4 87 vs. 35 0.01 — — 80 80
15% LVESV — Ts-4 — — 0.70 0.001 92 92
Heist (75) dP/dt 25% 54 Ts-4 — — 0.60 0.0001 100 38
dP/dt — — 0.47 0.002 89 76
Notabartolo (22) 15% LVESV 41 Ts-6 289 vs. 188 0.01 — — 97 55
NYHA 1, 6MWT 50 m, QOL 15 24 Ts-6 264 vs. 198 — — — 78 33
Yuan (109) 5% LVEF 39 Ts-6 annular 111 vs. 86 0.005 0.79 0.033 86 73
Yu (87) 15% LVESV 43 Ts-SD-12 45.0 vs. 24.8 0.001 0.76 0.001 100 100
Yu (63) 15% LVESV 43 Ts-SD-12 — — 0.74 0.001 96 78
Yu (88) 15% LVESV 47 Ts-SD-12 — — 0.76 0.001 96 78
Ts-12 — — 0.64 0.001 90 76
Yu (17) 15% LVESV 45 Ts-SD-12 46 vs. 29 0.001 — — 93 73
Ts-12 137 vs. 91 0.001 — — 92 68
Ts-2 90 vs. 42 0.001 — — 70 76
De Boeck (45) 15% LVESV 41 Ts-SD-12 47 vs. 42 NS 0.27 0.086 83 24
Ts-2 29 vs. 32 NS 0.12 0.453 33 65
IVMD 67 vs. 41 0.01 0.46 0.003 91 47
Strain-2 330 vs. 182 0.01 0.45 0.003 96 47
Continued on next page
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Continued
Table 4 Continued
First Author (Ref. #) Responder Definition % Nonresponders
Dyssynchrony
Parameter
Responders vs. Nonresponders Correlation* Accuracy
Parameter (ms) p Value r p Value Sn Sp
Penicka (69) 25% LVEF 45 To-3 84 vs. 38 0.0001 — — 85† 77†
To LV-RV 84 vs. 43 0.0001 — — 85† 64†
To Sum 167 vs. 81 0.0001 0.73 0.0001 96 77
Jansen (67) 15% LVESV 45 To-SD-6 37 vs. 20 0.0001 0.59 0.0001 97 74
To-6 — — 0.59 0.0001 95 73
Jansen (110) 10% LVESV 30 Shuffle — — — — 87 69
Cannesson (91) 15% LVEF 43 Velocity vector 131 vs. 52 0.05 — — 85 80
Tissue synchronization imaging
Tada (61) 15% LVESV 45 TSI Ts Sep Lat 303 vs. 176 0.05 — — 100 90
Gorcsan (92) 15% stroke volume 48 TSI Ts-2 161 vs. 18 0.001 — — 87 100
Van de Veire (25) NYHA 1 and 6MWT 25% 43 TSI Ts-2 79 vs. 28 0.001 — — 80 92
15% LVESV 47 TSI Ts-2 78 vs. 37 0.001 — — 81 89
Yu (62) 15% LVESV 46 TSI Ts-SD-12 47.3 vs. 29.2 0.001 0.61 0.001 87 81
TSI Ts-12 133.9 vs. 83.7 0.001 0.60 0.001 83 85
TSI Ts-SD-6 42.9 vs. 26.6 0.001 0.52 0.001 70 92
TSI Ts-6 105.2 vs. 65.5 0.001 0.53 0.001 73 77
3-dimensional
Van de Veire (77) 15% LVESV 53 3D TSI Ts-SD-12 44 vs. 23 0.0001 0.59 0.001 91 85
Van de Veire (76) NYHA 1 37 Ts-SD-12 3D 42 vs. 22 0.001 — — 89 82
15% LVESV 42 Ts-SD-12 3D 44 vs. 20 0.001 0.52 — 90 83
Marsan (78) 15% LVESV 37 3D SDI 9.7 vs. 3.4 0.0001 0.60 0.0001 88 86
Strain rate imaging
Porciani (98) 15% LVESV 53 oExcT 1,087 vs. 663 0.001 0.48 0.0001 94 83
Ts-SD-12 50 vs. 37 0.01 0.32 0.01 82 39
Mele (56) 15% LVESV or 20% LVEF 35 T-SD-12 — — 0.73 0.001 — —
Dohi (93) 15% stroke volume 45 T-2 Sep-Post 249 vs. 137 0.005 0.93 0.0001 95 88
Capasso (27) NYHA 1 and 6MWT 25% 21 T-2 87 vs. 91 NS — — — —
Speckle tracking
Knebel (101) 15% LVESV 53 T-6 168 vs. 179 NS — — — —
Ts-6 121 vs. 107 — — — 64 80
Suffoletto (83) 15% LVEF 24 T-2 Sep-Post 223 vs. 120 0.05 — — 89 83
Gorcsan (59) 15% LVEF 34 T-2 Sep-Post — — — — 84 73
Delgado (90) 15% LVESV 45 T-2 Sep-Post 251 vs. 94 0.001 0.41 0.001 83 80
*Correlation between dyssynchrony parameter and responder definition; †accuracy parameters calculated from data presented.
LVESV  left ventricular end-systolic volume; QOL  quality of life; Sn  sensitivity; Sp  specificity; other abbreviations as in Table 1.
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n Patients With Narrow QRS Complexes
hat is a narrow QRS? The 120 ms QRS threshold
dopted by international guidelines is based on the enrollment
riteria of landmark clinical trials. However, the true meaning
f “narrow” QRS duration is controversial. The median QRS
uration in both the COMPANION (Comparison of Medi-
al Therapy, Pacing, and Defibrillation in Heart Failure) and
ARE-HF studies was 160 ms, while the mean QRS duration
anged from 155 to 175 ms in the remaining trials (Table 1).
his has prompted many to question the benefit of CRT in
atients with an “intermediate” QRS duration between 120
nd 150 ms (105). In the CARE-HF and COMPANION
rials, only those patients with QRS 160 ms and 169 ms,
espectively, experienced a significant risk reduction (9,10).
uch retrospective, subgroup-derived dichotomies are mislead-
ng. While efficacy and dyssynchrony may correlate, this does
ot justify extrapolating arbitrary, non–pre-specified cutoffs to
atient care. QRS duration is a continuous variable whose
hreshold must reflect the entry criteria of landmark clinical
rials. In these trials the number and outcomes of patients with
n intermediate QRS duration is unknown.
chocardiographic selection in narrow QRS patients.
hree nonrandomized, single-center studies have compared
RT in patients with broad and narrow QRS durations (120
s cutoff), the latter selected using tissue Doppler or conven-
ional parameters (Table 5) (106–109). All 3 studies were
mall, including between 14 and 51 patients. All 3 reported no
ignificant difference in clinical and remodeling end points,
ncluding NYHA functional class and LVEF. However, the
argest narrow QRS study to date yielded similar results
ithout echocardiographic selection. In 331 and 45 patients
ith a wide and narrow QRS, respectively, increases in NYHA
unctional class, LVESV, and 6-min walk distance were
imilar over a mean 28-month follow-up (110). The echocar-
iographic studies were critically flawed. None included a
RT in Patients With Narrow QRSd
Table 5 CRT in Patients With Narrow QRSd
Study/First Author
(Ref. #) n
n With
Narrow QRSd Randomized
Control Group
QRSd P
RethinQ (66) 172 172
130 ms
Yes CRT off
Narrow
Yu (104) 102 51
120 ms
No Wide
120 ms
Bleeker (105) 66 33
120 ms
No Wide
120 ms
Achilli (106) 52 14
120 ms
No Wide
120 ms
Gasparini (107) 376 45
120 ms
No Wide
120 ms
Gasparini (111) 158 30
150 ms
No Wide
150 ms
VESV  left ventricular end-systolic volume; MR  mitral regurgitation; other abbreviations as inarrow QRS control group without echocardiographic dyssyn- bhrony or without CRT activated. No hard clinical end point
as evaluated. Most importantly, failure to detect a difference
oes not imply equivalence.
The only randomized trial in patients with a narrow QRS
onfirms these misgivings. After device implantation, the
ethinQ (Cardiac Resynchronization Therapy in Patients
ith Heart Failure and Narrow QRS) trial randomly assigned
72 patients with echocardiographic dyssynchrony to CRT or
o CRT (66). Most patients (96%) were selected using tissue
oppler criterion (Ts-465 ms). After 6 months, neither the
rimary end point of peak oxygen consumption nor other
ndicators such as reverse remodeling or 6-min walk distance
mproved. In summary, no robust evidence supports echocar-
iographic selection in patients with a narrow QRS. An
ppropriate trial would require a reproducible measurement of
yssynchrony tested prospectively with hard clinical end points.
autions Regarding the QRS Duration
he QRS duration is not perfect. It represents the vectorial
um of electrical forces generated by myocardial masses over
ime. Simplicity is both a strength and weakness. The electro-
ardiogram is an inexpensive, rapid, and reproducible tool
btainable in every patient by anyone with basic technical
raining. More importantly, in randomized controlled trials,
he QRS duration identified patients likely to gain significant
orbidity and mortality benefits from CRT. Nevertheless,
RS duration is only a surrogate for timing of myocardial
ontraction. Correlations with interventricular and intraven-
ricular mechanical dyssynchrony are limited (111). The elec-
rocardiogram is unable to characterize the presence, direction,
nd severity of delay in each ventricular segment. Regional
bnormalities with small electrical vectors are undefined.
chocardiography in principal offers solutions to these prob-
ems. Newer modalities such as speckle tracking will hopefully
rove more feasible and reproducible in randomized controlled
rials and clinical practice. Only then will the benefits of CRT
ctive Blinded
Follow-Up
(Months)
Echocardiographic
Parameter Main End Points
Yes 6 Ts-4
SPWMD
Peak Vo2 1.0
46% vs. 41%, p  0.63
No 3 Ts-SD-12
32.6 ms
No significant difference:
6MWT, NYHA, LVEF,
LVESV
Yes 6 Ts-4
65 ms
No significant difference:
6MWT, NYHA, LVEF,
LVESV
Yes 18mean IVMD
LLWDC
No significant difference:
NYHA, LVEF, LVESD, MR
No 28mean None No significant difference:
mortality, 6MWT, NYHA,
LVESV
No 11mean None No significant difference:
6MWT, QOL, LVEF, LVESV
1 and 3.rospe
Yes
Yes
Yes
Yes
Yes
Yese extended to patients with a narrow QRS duration.
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nternational guidelines are clear and unanimous in defining
ho should receive CRT (11–15). The Class I, Level of
vidence: A recommendations contain only 1 measure of
yssynchrony: QRS prolongation. Landmark clinical trials
ave demonstrated unequivocal morbidity and mortality ben-
fits in over 4,000 patients enrolled on the basis of their
lectrocardiogram. Echocardiographic dyssynchrony has been
he subject of numerous publications and is proposed by some
s a superior means of selecting patients for CRT. Echocar-
iographic parameters have largely been studied in small,
onrandomized studies with surrogate end points. Major
ethodological limitations include lack of basic validation and
emonstration of reproducibility. The largest trial of such
easures, the PROSPECT trial, demonstrated striking vari-
bility, poor reproducibility, and limited predictive power when
pplied in clinical practice. Echocardiographic measures should
ot be used to deny patients potentially life-saving therapy or
xpose them to unnecessary risks. Patient selection must use
he parameter prospectively validated in landmark clinical
rials: the QRS duration.
eprint requests and correspondence: Dr. Nathaniel M.
awkins, Aintree Cardiac Centre, University Hospital Aintree,
ongmoor Lane, Liverpool L9 7AL, United Kingdom. E-mail:
athawkins@hotmail.com.
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